
Twenty-six patients with advanced zzso received zzso given as an intravenous zzso zzso in zzso saline at 3 weekly zzso The starting dose was 30 zzso with standard graded zzso to 900 zzso zzso occurred at 800 zzso with a mean zzso of zzso zzso zzso X zzso and a mean zzso zzso count of 41 zzso 31 X zzso At 800 or 900 zzso zzso and vomiting was WHO grade 0 in 5, grade I in 6, grade II in 11 and grade III in 10 courses of zzso zzso did not zzso zzso was given by zzso infusion at 800 zzso in 2 patients, both of whom developed severe zzso Five patients given zzso by zzso zzso developed mild zzso No zzso zzso or cardiac toxicity was zzso Two patients had partial zzso both had zzso of unknown primary origin, one of whom had been resistant to prior therapy with zzso An zzso zzso method was developed with a sensitivity of 250 zzso The data from 7 patients studied best fit a one compartment zzso model with an exponential zzso and a zzso of only zzso zzso In conclusion, the dose limiting toxicity of zzso appears to be zzso and we would recommend a dose of 800 zzso given as an intravenous zzso every 4 weeks for future phase II zzso 

